Market research
DMPI Kintara Therapeutics, Inc
NASDAQ USD Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 1.85
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 1.85
About
About Kintara Therapeutics, Inc
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.
Research context
Kintara Therapeutics, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DMPI discussion.
5 years, 6 months ago
Kintara Therapeutics, Inc is currently in a long term uptrend where the price is trading 42.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kintara Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 211.1% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 217.6% to $-5M since the same quarter in the previous year.
Based on the above factors, Kintara Therapeutics, Inc gets an overall score of 2/5.